{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:15:21Z","timestamp":1788419721755,"version":"build-2803163510"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012524","name":"American Lebanese Syrian Associated Charities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012524","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["1K08CA279927-01A1"],"award-info":[{"award-number":["1K08CA279927-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA021765"],"award-info":[{"award-number":["P30CA021765"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA021765"],"award-info":[{"award-number":["P30CA021765"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA021765"],"award-info":[{"award-number":["P30CA021765"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"DOI":"10.1038\/s41375-026-03108-9","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:36:02Z","timestamp":1788417362000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CD19-CAR T cells persist long-term in the cerebrospinal fluid of pediatric, adolescent and young adult patients with B-cell acute lymphoblastic leukemia"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6558-6706","authenticated-orcid":false,"given":"Aimee C.","family":"Talleur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9627-3104","authenticated-orcid":false,"given":"Jean-Yves","family":"M\u00e9tais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Schell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polly","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8998-0732","authenticated-orcid":false,"given":"Rebecca","family":"Epperly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1852-5222","authenticated-orcid":false,"given":"Marleni","family":"Torres Nunez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3991-7468","authenticated-orcid":false,"given":"Stephen","family":"Gottschalk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9979-7360","authenticated-orcid":false,"given":"Swati","family":"Naik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"3108_CR1","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1038\/s41375-022-01714-x","volume":"36","author":"M Thastrup","year":"2022","unstructured":"Thastrup M, Duguid A, Mirian C, Schmiegelow K, Halsey C. Central nervous system involvement in childhood acute lymphoblastic leukemia: challenges and solutions. Leukemia. 2022;36:2751\u201368.","journal-title":"Leukemia"},{"key":"3108_CR2","doi-asserted-by":"publisher","first-page":"e29256","DOI":"10.1002\/pbc.29256","volume":"68","author":"C Hastings","year":"2021","unstructured":"Hastings C, Chen Y, Devidas M, Ritchey AK, Winick NJ, Carroll WL, et al. Late isolated central nervous system relapse in childhood B-cell acute lymphoblastic leukemia treated with intensified systemic therapy and delayed reduced dose cranial radiation: a report from the Children\u2019s Oncology Group study AALL02P2. Pediatr Blood Cancer. 2021;68:e29256.","journal-title":"Pediatr Blood Cancer"},{"key":"3108_CR3","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa035091","volume":"349","author":"CH Pui","year":"2003","unstructured":"Pui CH, Cheng C, Leung W, Rai SN, Rivera GK, Sandlund JT, et al. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med. 2003;349:640\u20139.","journal-title":"N Engl J Med"},{"key":"3108_CR4","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1200\/JCO.23.00594","volume":"41","author":"LD Maese","year":"2023","unstructured":"Maese LD, Pulsipher MA. Blinatumomab conundrum in low-risk relapsed B-Cell ALL. J Clin Oncol. 2023;41:4087\u201392.","journal-title":"J Clin Oncol"},{"key":"3108_CR5","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1200\/JCO.22.00642","volume":"41","author":"TW Laetsch","year":"2023","unstructured":"Laetsch TW, Maude SL, Rives S, Hiramatsu H, Bittencourt H, Bader P, et al. Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA Trial. J Clin Oncol. 2023;41:1664\u20139.","journal-title":"J Clin Oncol"},{"key":"3108_CR6","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1200\/JCO.20.03585","volume":"40","author":"LM Schultz","year":"2022","unstructured":"Schultz LM, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, et al. Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report. J Clin Oncol. 2022;40:945\u201355.","journal-title":"J Clin Oncol"},{"key":"3108_CR7","doi-asserted-by":"publisher","first-page":"e711","DOI":"10.1016\/S2352-3026(21)00238-6","volume":"8","author":"AB Leahy","year":"2021","unstructured":"Leahy AB, Newman H, Li Y, Liu H, Myers R, DiNofia A, et al. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials. Lancet Haematol. 2021;8:e711\u201322.","journal-title":"Lancet Haematol"},{"key":"3108_CR8","doi-asserted-by":"publisher","first-page":"6320","DOI":"10.1182\/bloodadvances.2023010461","volume":"7","author":"R Epperly","year":"2023","unstructured":"Epperly R, Shulkin BL, Bag AK, Cheng C, Inaba H, Lucas JT, et al. CD19 CAR T-cell therapy demonstrates activity against extramedullary disease in pediatric patients with B-ALL. Blood Adv. 2023;7:6320\u20134.","journal-title":"Blood Adv"},{"key":"3108_CR9","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1182\/blood-2025-648","volume":"146","author":"A DiNofia","year":"2025","unstructured":"DiNofia A, Myers R, Li Y, Liu H, Aplenc R, Baniewicz D, et al. CD19 CAR T cell therapy is an effective strategy for first CNS relapse in pediatric b ALL. Blood. 2025;146:648.","journal-title":"Blood"},{"key":"3108_CR10","doi-asserted-by":"publisher","first-page":"5737","DOI":"10.1182\/bloodadvances.2021006293","volume":"6","author":"A Talleur","year":"2022","unstructured":"Talleur A, Qudeimat A, Metais JY, Langfitt D, Mamcarz E, Crawford JC, et al. Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL. Blood Adv. 2022;6:5737\u201349.","journal-title":"Blood Adv"},{"key":"3108_CR11","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3108_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/MPH.0000000000002765","volume":"46","author":"S Leib","year":"2024","unstructured":"Leib S, Bielorai B, Vernitsky H, Aharony-Tevet Y, Toren A, Jacoby E. Cerebral spinal fluid parameters following CD19-targeted therapies in children and young adults. J Pediatr Hematol\/Oncol. 2024;46:29\u201332.","journal-title":"J Pediatr Hematol\/Oncol"},{"key":"3108_CR13","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1080\/10428194.2024.2392823","volume":"65","author":"D Ngo","year":"2024","unstructured":"Ngo D, Tinajero J, Song JY, Ma H, Quirk E, Koller P, et al. The characterization and the impact of CSF pleocytosis during blinatumomab therapy for adult acute lymphoblastic leukemia. Leuk Lymphoma. 2024;65:2016\u201324.","journal-title":"Leuk Lymphoma"},{"key":"3108_CR14","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/cncr.33967","volume":"128","author":"I Aldoss","year":"2022","unstructured":"Aldoss I, Otoukesh S, Zhang J, Mokhtari S, Ngo D, Mojtahedzadeh M, et al. Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia. Cancer. 2022;128:529\u201335.","journal-title":"Cancer"},{"key":"3108_CR15","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1001\/jama.2021.0669","volume":"325","author":"PA Brown","year":"2021","unstructured":"Brown PA, Ji L, Xu X, Devidas M, Hogan LE, Borowitz MJ, et al. Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of b-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325:833\u201342.","journal-title":"JAMA"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03108-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03108-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03108-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:36:03Z","timestamp":1788417363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03108-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":15,"alternative-id":["3108"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03108-9","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"assertion":[{"value":"27 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SG and RE have patents or patent applications in the fields of cell or gene therapy for cancer. SG is a member of the Scientific Advisory Board of Be Biopharma and the Data and Safety Monitoring Board (DSMB) of Immatics. Remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}